View in EDS

Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci.

Saved in:
Bibliographic Details
Title: Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci.
Authors: Lessard, Samuel1,2, Tardif, Jean-Claude1,2, Lettre, Guillaume1,2, Francioli, Laurent3,4, Alfoldi, Jessica3,4, MacArthur, Daniel G.3,4, Ellinor, Patrick T.4,5, Canver, Matthew C.6,7,8,9, Orkin, Stuart H.6,7,8,9,10
Source: Proceedings of the National Academy of Sciences of the United States of America. 12/26/2017, Vol. 114 Issue 52, p11257-11266. 10p.
Subjects: CRISPRs, Human genetic variation, Locus (Genetics), Genome editing, Single nucleotide polymorphisms
Abstract: The CRISPR-Cas9 nuclease system holds enormous potential for therapeutic genome editing of a wide spectrum of diseases. Large efforts have been made to further understanding of on- and offtarget activity to assist the design of CRISPR-based therapies with optimized efficacy and safety. However, current efforts have largely focused on the reference genome or the genome of cell lines to evaluate guide RNA (gRNA) efficiency, safety, and toxicity. Here, we examine the effect of human genetic variation on both onand off-target specificity. Specifically, we utilize 7,444 whole-genome sequences to examine the effect of variants on the targeting specificity of ~3,000 gRNAs across 30 therapeutically implicated loci. We demonstrate that human genetic variation can alter the off-target landscape genome-wide including creating and destroying protospacer adjacent motifs (PAMs). Furthermore, single-nucleotide polymorphisms (SNPs) and insertions/deletions (indels) can result in altered on-target sites and novel potent off-target sites,which can predispose patients to treatment failure and adverse effects, respectively; however, these events are rare. Taken together, these data highlight the importance of considering individual genomes for therapeutic genome-editing applications for the design and evaluation of CRISPR-based therapies to minimize risk of treatment failure and/or adverse outcomes. [ABSTRACT FROM AUTHOR]
Copyright of Proceedings of the National Academy of Sciences of the United States of America is the property of National Academy of Sciences and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
FullText Text:
  Availability: 0
Header DbId: egs
DbLabel: Engineering Source
An: 127000737
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Lessard%2C+Samuel%22">Lessard, Samuel</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Tardif%2C+Jean-Claude%22">Tardif, Jean-Claude</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Lettre%2C+Guillaume%22">Lettre, Guillaume</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Francioli%2C+Laurent%22">Francioli, Laurent</searchLink><relatesTo>3,4</relatesTo><br /><searchLink fieldCode="AR" term="%22Alfoldi%2C+Jessica%22">Alfoldi, Jessica</searchLink><relatesTo>3,4</relatesTo><br /><searchLink fieldCode="AR" term="%22MacArthur%2C+Daniel+G%2E%22">MacArthur, Daniel G.</searchLink><relatesTo>3,4</relatesTo><br /><searchLink fieldCode="AR" term="%22Ellinor%2C+Patrick+T%2E%22">Ellinor, Patrick T.</searchLink><relatesTo>4,5</relatesTo><br /><searchLink fieldCode="AR" term="%22Canver%2C+Matthew+C%2E%22">Canver, Matthew C.</searchLink><relatesTo>6,7,8,9</relatesTo><br /><searchLink fieldCode="AR" term="%22Orkin%2C+Stuart+H%2E%22">Orkin, Stuart H.</searchLink><relatesTo>6,7,8,9,10</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22">Proceedings of the National Academy of Sciences of the United States of America</searchLink>. 12/26/2017, Vol. 114 Issue 52, p11257-11266. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22CRISPRs%22">CRISPRs</searchLink><br /><searchLink fieldCode="DE" term="%22Human+genetic+variation%22">Human genetic variation</searchLink><br /><searchLink fieldCode="DE" term="%22Locus+%28Genetics%29%22">Locus (Genetics)</searchLink><br /><searchLink fieldCode="DE" term="%22Genome+editing%22">Genome editing</searchLink><br /><searchLink fieldCode="DE" term="%22Single+nucleotide+polymorphisms%22">Single nucleotide polymorphisms</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The CRISPR-Cas9 nuclease system holds enormous potential for therapeutic genome editing of a wide spectrum of diseases. Large efforts have been made to further understanding of on- and offtarget activity to assist the design of CRISPR-based therapies with optimized efficacy and safety. However, current efforts have largely focused on the reference genome or the genome of cell lines to evaluate guide RNA (gRNA) efficiency, safety, and toxicity. Here, we examine the effect of human genetic variation on both onand off-target specificity. Specifically, we utilize 7,444 whole-genome sequences to examine the effect of variants on the targeting specificity of ~3,000 gRNAs across 30 therapeutically implicated loci. We demonstrate that human genetic variation can alter the off-target landscape genome-wide including creating and destroying protospacer adjacent motifs (PAMs). Furthermore, single-nucleotide polymorphisms (SNPs) and insertions/deletions (indels) can result in altered on-target sites and novel potent off-target sites,which can predispose patients to treatment failure and adverse effects, respectively; however, these events are rare. Taken together, these data highlight the importance of considering individual genomes for therapeutic genome-editing applications for the design and evaluation of CRISPR-based therapies to minimize risk of treatment failure and/or adverse outcomes. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Proceedings of the National Academy of Sciences of the United States of America is the property of National Academy of Sciences and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=127000737
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1073/pnas.1714640114
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 11257
    Subjects:
      – SubjectFull: CRISPRs
        Type: general
      – SubjectFull: Human genetic variation
        Type: general
      – SubjectFull: Locus (Genetics)
        Type: general
      – SubjectFull: Genome editing
        Type: general
      – SubjectFull: Single nucleotide polymorphisms
        Type: general
    Titles:
      – TitleFull: Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lessard, Samuel
      – PersonEntity:
          Name:
            NameFull: Tardif, Jean-Claude
      – PersonEntity:
          Name:
            NameFull: Lettre, Guillaume
      – PersonEntity:
          Name:
            NameFull: Francioli, Laurent
      – PersonEntity:
          Name:
            NameFull: Alfoldi, Jessica
      – PersonEntity:
          Name:
            NameFull: MacArthur, Daniel G.
      – PersonEntity:
          Name:
            NameFull: Ellinor, Patrick T.
      – PersonEntity:
          Name:
            NameFull: Canver, Matthew C.
      – PersonEntity:
          Name:
            NameFull: Orkin, Stuart H.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 26
              M: 12
              Text: 12/26/2017
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-print
              Value: 00278424
          Numbering:
            – Type: volume
              Value: 114
            – Type: issue
              Value: 52
          Titles:
            – TitleFull: Proceedings of the National Academy of Sciences of the United States of America
              Type: main
ResultId 1